GLPwatch
Papers (9189)
Page 85 of 154, ranked by citation count.
- Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin.
- A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes.
- Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus.
- Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) Improve Periodontal and Peri-Implant Health in Type 2 Diabetes Mellitus.
- Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease.
- Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
- Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.
- Site-selective modification of exendin 4 with variable molecular weight dextrans by oxime-ligation chemistry for improving type 2 diabetic treatment.
- Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
- An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database.
- Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner.
- Notch signaling is involved in the antiapoptotic effects of liraglutide on rat H9c2 cardiomyocytes exposed to hypoxia followed by reoxygenation.
- Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
- Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus.
- Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study.
- Effects of Oral Semaglutide on Renal Function in Diabetic Kidney Disease: A Short-term Clinical Study.
- Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
- Journal withdraws article after complaints from drug manufacturers.
- Roux-en-Y Gastric Bypass and Caloric Restriction but Not Gut Hormone-Based Treatments Profoundly Impact the Hypothalamic Transcriptome in Obese Rats.
- Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China.
- Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy.
- Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs.
- Liraglutide for weight loss in obese people.
- Interactions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism.
- Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.
- Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis.
- Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
- A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
- Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway.
- Exploring Liraglutide's mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway.
- Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
- Liraglutide in Children and Teens with Type 2 Diabetes.
- Liraglutide protects against diabetes mellitus complicated with focal cerebral ischemic injury by activating mitochondrial ATP-sensitive potassium channels.
- No clinical harm from a massive exenatide overdose: a short report.
- SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease.
- Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.
- Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease.
- Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis.
- GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state <i>via</i> GSK-3β pathway.
- A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice.
- Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery.
- Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.
- Importance and methods of searching for E-publications ahead of print in systematic reviews.
- Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
- Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).
- Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
- Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
- Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register - an IMI-SOPHIA study.
- β cell membrane remodelling and procoagulant events occur in inflammation-driven insulin impairment: a GLP-1 receptor dependent and independent control.
- Minimal modeling of insulin secretion in the perfused rat pancreas: a drug effect case study.
- Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs.
- The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus.
- Tolerance develops toward GLP-1 receptor agonists' glucose-lowering effect in mice.
- Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.
- Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data.
- Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control.
- Osmoadaptive GLP-1R signalling in hypothalamic neurones inhibits antidiuretic hormone synthesis and release.
- Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion.
- Brainstem BDNF neurons are downstream of GFRAL/GLP1R signalling.
- Hyperpolarized <sup>13</sup>C and <sup>31</sup>P MRS detects differences in cardiac energetics, metabolism, and function in obesity, and responses following treatment.